Management of in-transit melanoma of the extremity with isolated limb perfusion

Current Treatment Options in Oncology

Volumn 5, Issue 3, 2004, Pages 173-184

  Fraker, Douglas L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; GAMMA INTERFERON; INTERLEUKIN 2; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR;

BLISTER; BONE MARROW TOXICITY; CANCER STAGING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; ERYTHEMA; FEVER; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; LIMB BLOOD FLOW; LIMB PERFUSION; LYMPH NODE; LYMPH VESSEL; MELANOMA; METASTASIS; MYOPATHY; NAUSEA AND VOMITING; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; RECURRENCE RISK; REVIEW; SKIN ABRASION; SUBCUTANEOUS NODULE; SURGICAL TECHNIQUE; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; LIMB; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REGIONAL PERFUSION; SKIN TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 4444250076     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0009-3     Document Type: Review

References (35)

1. Creech O Jr, Krementz ET, Ryan RF, Winblad JN: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Sug 1958, 148: 616-632.
2. Krementz ET, Carter RD, Sutherland CM, et al.: Regional chemotherapy for melanoma: a 35-year experience. Ann Surg 1994, 220: 520-534.
3. Fraker DL: Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999, 36: 841-908.
4. Balch C, Buzaid AC, Soong SJ, et al.: Prognostic factors analysis of 17,600 melanoma patients: validation of the AJCC melanoma staging system. J Clin Oncol 2001, 19: 3622-3634.
5. Koops HS, Vaglini M, Suciu S, et al.: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998, 16: 2906-2912.
6. Hafstrom L, Rudenstam CM, Blomquist E, et al.: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991, 9: 2091-2094.
7. Jaques DP, Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989, 169: 1-6.
8. Stehlin JS, Giovanella BC, de Ipolyi PD, et al.: Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975, 140: 339-348.
9. Daryanani D, Komdeur R, Ter Veen J, et al.: Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001, 8: 564-565.
10. Roberts MS, Wu ZY, Siebert GA, et al.: Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001, 11: 423-431.
11. Wieberdink J, Benckhuysen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982, 18: 905-910.
12. Norda A, Loos U, Sastry M, et al.: Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 1999, 43: 35-42.
13. Lejeune FJ, Ghanem GE: A simple and accurate new method for cytostatic dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res 1987, 47: 639-643.
14. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992, 16: 227-233.
15. Hoekstra HJ, Koops HS, deVries LGE, et al.: Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993, 72: 1224-1229.
16. Lienard D, Lejeune F, Delmotte J, et al.: High doses of rTNFa in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10: 52-60.
17. Lienard D, Lejeune F, Ewalenko I: In transit metastases of malignant melanoma treated by high doses of rTNFa in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992, 16: 234-240.
18. Ghussen F, Kruger I, Groth W, et al.: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988, 61: 654-659.
19. Klaase JM, Kroon BB, van Geel AN, et al.: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994, 115: 39-45.
20. Klaase JM, Kroon BB, van Geel AN, et al.: Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994, 178: 564-572.
21. Fraker DL, Alexander HR, Pass HI: Biologic therapy of tumor necrosis factor: clinical applications by systemic and regional administration. In Biologic Therapy of Cancer. Edited by DeVita V, Hellman S, Rosenberg SA. Philadelphia: JB Lippincott; 1995:329.
22. Lejeune FJ: High dose recombinant tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995, 31A: 1009-1016.
23. Posner MC, Lienard D, Lejeune FJ, et al.: Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am 1995, 1: 274.
24. Lienard D, Eggermont AM, Koops HS, et al.: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999, 9: 491-502.
25. Fraker DL, Alexander HR, Bartlett DL, et al.: A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-γ (IFN): an initial report [abstract]. Soc Surg Oncol 1996, 49: 6.
26. Fraker, DL, Alexander HR, Ross M, et al.: A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon-gamma (IFN). Ann Surg Oncol 2002, 9: S8.
27. Fraker DL, Alexander HR, Andrich M, et al.: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study. J Clin Oncol 1996, 14: 479-489.
28. Ma G, Alexander HR, Bartlett DL, et al.: Isolated limb perfusion (ILRe) with tumor necrosis factor (TNF) and melphalan (M) for extremity melanoma after failure of isolated limb perfusion (ILP) with chemotherapeutics [abstract]. Soc Surg Oncol 1996, 49: 53.
29. Vaglini M, Belli F, Ammatuna M, et al.: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994, 73: 483-492.
30. Olieman AF, Koops HS, Geertzen JH, et al.: Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994, 3: 382-388.
31. Vrouenraets BC, in't Veld GJ, Nieweg OE, et al.: Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999, 25: 503-508.
32. Bonifati DM, Ori C, Rossi CR, et al.: Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol 2000, 46: 517-522.
33. Vrouenraets BC, Hart GA, Eggermont AM, et al.: Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. JAMA 1999, 188: 522-530.
34. Thom AK, Alexander HR, Andrich MP, et al.: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma and melphalan. J Clin Oncol 1995, 13: 264-273.
35. Stam TC, Swaak AJ, deVries MR, et al.: Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000, 7: 268-275.